Merck: Gonal-f Approved in Japan for Ovulation Induction in Infertile Women
The extended marketing authorization includes Gonal-f in 75 IU (International Units) vial and Gonal-f prefilled pen in 300 IU, 450 IU and 900 IU.
In Japan, Gonal-f has been indicated since 2006 to treat male hypogonadotropic hypogonadism (MHH) in combination with human Chorionic Gonadotropin (hCG), for the induction of spermatogenesis. The supplemental New Drug Application (sNDA) for ovulation induction in females was filed by Merck Serono in October 2008.
GONAL-f is currently approved in 77 countries for the treatment of male infertility and in 100 countries to treat female infertility.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.